A word from our team
CDO Corner
At XponentL, we firmly believe in the power of collaboration. Our partnerships are more than just strategic alliances; they represent a shared vision and mutual growth towards transforming the data landscape. Keeping abreast of our partners' advancements and achievements is crucial, as they often signify progress in the broader data industry, and more importantly, the direct impact of our collaborative efforts. In each edition of our newsletter, we endeavor to bring you the latest updates from our partner network. This feature is designed to keep you informed about their most recent initiatives, product launches, industry recognitions, and thought leadership insights. By doing so, we hope to underscore the value of our combined efforts and the influence of these partnerships on industry trends. This month, our partners have made significant strides in a variety of areas, from launching innovative data products to earning noteworthy accolades for their contributions to the industry. We are proud to share these achievements with you, and hope they provide valuable insights into the dynamic, forward-thinking nature of our extended network. Stay tuned to this section to get an inside look at the pioneering work our partners are doing, as we collectively drive towards a more data-centric future. In a remarkable series of developments among our partners, DataBricks made a significant stride forward, as Grammarly announced their transition from their in-house data lake to using the Databricks Platform that relies on Medallion Architecture. Importantly, DataBricks has also acquired Mosaic, marking a key expansion in their portfolio.The platform of cloud data firm Snowflake received a significant boost as Nvidia integrated its AI computing platform, enhancing Snowflake's capabilities further. AWS launched generative AI-powered healthcare services that open up new possibilities in the healthcare industry. In a joint move with Google and Microsoft, AWS has also become part of a new AI group that aims to develop safety standards proactively, ahead of policymakers. Microsoft also introduced a free AI training program offering a professional certificate, promising to democratize AI education. In a similar move, Dataiku integrated with OpenAI to target responsibleAI, demonstrating a commitment towards ethical AI practices. Our partner, Tamr, announced an exciting investment by Alteryx Ventures, which will no doubt further fuel their growth and expansion. Collibra revealed its new data intelligence cloud capabilities and subsequently launched its Data Intelligence Cloud, showcasing their commitment to advancing data intelligence. Atlan introduced the future of data handling with its unveiling of Atlan AI. Our partners at DataOps.live are gearing up for their book launch, titled 'Data Products for Dummies,' which is to be premiered at the BigData London Conference 2023. In a surprising turn of events, Starburst announced a free version of its Starburst Enterprise Platform and further partnered with Privacera to protect sensitive data across distributed environments. Lastly, Neo4j took a huge leap forward, firstly by gens-ing up in Google Cloud LLM and subsequently by announcing the general availability of its Next-Generation GraphDatabase, Neo4j 5. These developments highlight the cease less innovation and growth that our partners continue to bring to the technology industry, ensuring that XponentL is at the forefront of these exciting changes.
Unleashing the Potential: Overcoming Healthcare Data Challenges for Optimal Value Realization
The Biopharmaceutical Revolution: Why Data Products?
The business of data

The business of data Vol 2

Dr. Morales, a seasoned biopharmaceutical executive, brings 23 years of comprehensive experience from technology to life sciences in Pharma/Biotech drug development. Notably, he led data integration, mastering, and modernization at WCG Clinical, while also steering the commercialization of the Quantitative Data Surveillance System (QDSS) for clinical trials. Post-PhD from MIT with Dr. Paul Schimmel, he began his industry career at Genome Therapeutics as a Senior Computational Biologist, and held several key roles, including the global lead for Biology Platform Informatics at the Novartis Institutes for Biomedical Research.
